1Riddle MC,Rosenstock J,Gerich J.The treat-to-target trial:randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients[J].Diabetes Care,2003,26 (11):3080-3086.
2Rosenstock J,Dailey G,Massi-Benedetti M,et al.Reduced hypoglycemia risk with insulin glargine:a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes[J].Diabetes Care,2005,28 (4):950-955.
3Rosenstock J,Sugimoto D,Strange P,et al.Triple therapy in type 2 diabetes:insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients[J].Diabetes Care JT-Diabetes care,2006,29 (3):554-559.
4Janka HU,Plewe G,Riddle MC,et al.Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes[J].Diabetes Care,2005,28 (2):254-259.
5Raskin P,Allen E,Hollander P,et al.Initiating insulin therapy in type 2 diabetes:a comparison of biphasic and basal insulin analogs[J].Diabetes Care,2005,28 (2):260-265.
6Raskin P,Rendell M,Riddle MC,et al.A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes[J].Diabetes Care JT-Diabetes care,2001,24 (7):1226-1232.
